發行人：王丹江 總編輯：陳本源

中華民國九十六年一月 第十四卷 第一期 1

έ̚ၷᓁᘽੈ!

VGHTC Drug Bulletin

發行人：王丹江 總編輯：陳本源

編 輯：鄭鴻基、湯念湖、陳宜慧、江妮娜、黃文龍、方乃傳 地 址：台中市中港路三段 160 號 藥劑部

網 址：http://www3.vghtc.gov.tw/pharmacy/pharmacy1.htm 電子信箱：phar@vghtc.gov.tw

創刊日期：八十三年一月二十日

ഴ۲۞щБϡᘽ!

ౘآᇊ ᘽर

۲ࡡ̏జ͵ࠧ኎Ϡ௡ᖐЕࠎώ͵ࡔ౵

ࢦࢋ۞̳В኎Ϡᛉᗟ̝˘Ăវࢦ࿅ࢦ۰Ꭾଈ ௐ˟ݭᎤԌঽĂᓙᝃ়ঽĂ݄ېજਔّ͕᝙

ঽĂ੼ᓙ׽ዔĂ੼ҕᑅĂ੻ᙯ༼ۆ۞፟தព

඾ᆧΐĄ҃۲ࡡ۰)͍׎ّ̃*टٽצזۤົ

ڡෛ̙̈́ܦ༚Ăᇆᜩ׎ˠᅫᙯܼĂᚑࢦ۞ᔘ Ξਕົጱ࡭ᇎ៭াĄ!

ౄј۲ࡡ۞Я৵Β߁ѣ(1)ૄЯĂ(2)ᒖ ဩĂ(3)͕நĂ(4)়ঽĂּтĂऱڟͩা࣏

ཏĞCushing’s syndromeğٕߏϥېཛྷΑਕ

࿅ҲඈĂ(5)ᘽۏ(тܑ˘)ĄෞҤ۲ࡡ඀ޘ۞

͞ڱѣ 2 ჌Ăௐ˘჌ͽ֗វኳณ޽ᇴෞҤ Ķវࢦ(̳͝)ੵͽ֗੼(̳͎)π͞ķĂ޽ᇴ̂

ٺ 25 ΃ܑវࢦ࿅ࢦĂтڍ̂ٺ 30 ݋ߏ۲ ࡡĂ̂ٺ 40 ݋ߏໂޘ۲ࡡĂௐ˟჌ෞҤ۲ ࡡ۞͞ڱߏീณཕಛĂᑭߤཛొ਌۹۞ુ

᎕Ăշّཕಛ෹࿅ 102 ̶̳Ẵّཕಛ෹࿅

88 ̶̳ܮ̙ЪॾĂᎮଈ়ঽ፟ົ೩੼Ą

۲ࡡᙷҬ੼ҕᑅٕᎤԌঽ˘ᇹߏၙّ

ঽĂΪѣ֗វኳณ޽ᇴ̂ٺ 27 ͷЪ׀׎΁

়ঽ̖ᅮࢋ҂ᇋ᎕ໂֹϡᘽۏԼචĄּтĂ ۲ࡡ۰Ъ׀˭Е়ঽĂ(1)݄ېજਔঽĂ(2) જਔർ̼াĂ(3)ௐ˟ݭᎤԌঽٕߏ(4)Ⴢ্

̚ײӛͤ̚া࣏ཏĂᅮࢋ᎕ໂ఍ந۲ࡡ̈́׎

Ъ׀াĄĞྎтܑ˟ğĄ

ϫ ݈ д έ ៉ Ъ ॾ ˯ ξ ۞ ഴ ۲ ᘽ ѣ Orlistat ̈́ Sibutramine ඈ 2 ჌ĞྎтܑˬğĂ

ࢋਕѣड़ڼᒚ۲ࡡĂυืЪ׀฼ࢴଠט̈́ྻ

જᄃҖࠎڼᒚĄഴࢦ౵рቤၙ҃޺ᜈĂࡶి

ޘ͉ԣĂྵटٽаೇֽࣧវࢦĂ˵टٽ׀൴ ᓙඕϮࠤҌౄј࿪ྋኳ̙πᏊĄഴࢦ۞ϫᇾ ࠎՏฉഴ͌ 1-2 ቀĂ6 ̰࣎͡ഴᅅ 10%۞វ ࢦĄڼᒚ۲ࡡ۞ᘽۏĂ̂࡭˯ΞᕩˬᙷĂԺ טࢴᇒ۞ᘽۏĞSibutramineğăԺטབ྽ᒉ ዳ৵ӛќ۞ᘽۏĞOrlistatğ̈́ᆧΐயሤड़ᑕ

۞ᘽۏĄ

第 一 期

૞ ᗟ ಡ ጱ !

第十四卷 第一期 台中榮總藥訊 2

Ω ˘ ี າ ۞ ڼ ᒚ ᘽ ۏ Ᏼ ፄ RimonabantĂдለ߷̏८ࣞ˯ξĂέ៉إ Ϗ ८ ࣞ ˯ ξ Ą Rimonabant ߏ ˘ ჌ endocannabinoid ତצጡ޻ԩ጗ć઼γᓜԖ ಡӘពϯιਕࢫҲࢴۏᛷפ۞ᇒ୕,ֹវࢦ ഴᅅ̈́ཕಛត̈,֭ਕܳซ਌۹̶ྋ̈́ཬ෈

Ꭴᙷ΃ᔁ,ͽ̈́Լචҕ਌ள૱ඈड़ڍćҭߏ, ᘃ Ⴗ Ξ ਕ ົ ᆧ ΐ ଐ ჰ ّ ় ঽ ൴ Ϡ ۞ Ξ ਕ

ّĄड़ڍ˯ĂSibutramine πӮѣ 4-5 ̳͝

̈́ Orlistat πӮࡗ 3 ̳͝۞ഴࢦүϡĂ Rimonabant πӮΞͽഴ 4-5 ̳͝Ą

ᘽۏдᓜԖᑕϡ˯Ăࡇѣ༊ঽˠ൑ڱͽ

฼ࢴϠ߿ݭၗഴࢦॡĂ̖ޙᛉڇϡᘽۏֽڼ ᒚĄ၆ٺઉ૵۞۲ࡡঽଈĂ݋ޙᛉᐹА҂ᇋ SibutraminećтڍĂ۲ࡡঽଈЪ׀ѣ੼ҕ ᑅĂ͕ҕგ়ঽٕҕ਌۹ள૱ॡĂޙᛉ҂ᇋ

ͽ Orlistat ࠎௐʑቢഴ۲ϡᘽĂ͹ࢋߏιд

͕ҕგ͞ࢬѣޝр۞щБّ҃ͷ˫ѣࢫҕ

਌۞үϡĄ၆ٺௐ˟ݭᎤԌঽ۞۲ࡡঽଈĂ

ੵ ˞ Լ ត ฼ ࢴ Ϡ ߿ ݭ ၗ Ă ޙ ᛉ ڇ ϡ MeforminĂߊΞଠטҕᎤ˫ΞዋޘഴࢦĂ࣐

ࡶࢋГซ˘Վഴࢦ,Ξͽֹϡ OrlistatĂтڍ ঽ ଈ ᔘ ׀ ѣ ੼ ҕ ᑅ Ă ݋ ̙ ޙ ᛉ ֹ ϡ Sibutramine Ą ᘽ ۏ ֹ ϡ ˯ Ă ֭ ̙ ޙ ᛉ Sibutramine ᄃ Orlistat Ъ׀ֹϡĂЯࠎࡁ տពϯ׀ϡ̙֭ົΐૻड़ڍĄϫ݈ഴ۲ڼᒚ

۞ड़ڍᔵ̙ߏޝநຐĂҭΪࢋਕഴᅅ 10%

۞វࢦĂӈΞࢫҲ۲ࡡ͔൴۞Ъ׀া၆ઉ૵

۞ރ਎Ą౵ޢυืૻአ۞ߏĂវࢦഴᅅ̝ޢ ޝटٽೇࡡĂ̙ΞԆБֶያᘽۏֽഴ۲Ăӎ

݋֙֙ࡴࡴഴ˭ֽĂޝԣ۞ೇࡡ˫ѣңຍ ཌྷĉ

!

ܑ˘ĈΞਕԼតវࢦٕࢴᇒ̝ᘽۏ!

̶ᙷ ᆧΐវࢦٕࢴᇒ̝ᘽۏ ഴ͌វࢦٕࢴᇒ̝ᘽۏ

ჟৠࡊϡᘽ Thioridazine, Clozapine, Olanzepine, Quetiapine, Risperidone

Molindone, Haloperidone, Ziprasodone, Aripiprazole

ԩᇎᇋᘽ Amitriptyline, Imipramine, Mitrazapine, Paroxetine

Fluoxetine, Bupropion,

Nefazadone,Protriptyline, Sertraline ԩឩ⿔ᘽ Valproate, Carbamazepine,

Gabapentin

Lamotrigine, Zonisamide, Topiramate,

ᎤԌঽᘽ Insulin, Metiglinide, Sulfonylureas, Thiazolidinediones

Acarbose, Metformin

ԩ௡ᖐ῔ᘽ Cyproheptidine Inhalers, decongestants Ϲຏৠགྷܡᕝ጗ Propranolol, Terazosin ACE inhibitors, Calcium channel

blockers

ෲႬᄋ Contraceptive, Glucocorticoids, Progestational steroids

第十四卷 第一期 台中榮總藥訊 2

ܑ˟Ĉវࢦ࿅ࢦ۞Ξਕڼᒚ͞ё

BMI 25-26.9 វࢦ࿅ࢦ

27-29.9 វࢦ࿅ࢦ

30-34.9 ۲ࡡ

35-39.9 ۲ࡡ

>40 ໂޘ۲ࡡ

ྻજ,฼ࢴଠט + + + + +

ᒉዳर฼ࢴ޽ጱ ѣЪ׀া + + + +

ϒёྻજࢍထ ѣЪ׀া + + + +

ᘽۏڼᒚ ѣЪ׀া + + +

ໂҲሤณ฼ࢴ ѣЪ׀া + +

͘ఙڼᒚ ѣЪ׀া +

ܑˬĈOrlistat ᄃ Sibutramine ͧྵܑ

Orlistat Sibutramine

̶ᙷ ਌۹ӛќԺט጗ ࢴᇒԺט጗

үϡ

፟ᖼ

Ժט਍᝙਌۹酶 Ժט serotoninănorepinephrine ̝Гӛќ

጗ณ Տ͟ˬѨĂՏѨ 120mg Տ͟˘ѨĂՏѨ 10-15mg পᕇ Ξдབ྽̚Ժטࢴۏ̚਌۹ࡗ 30%۞

ӛќ

ܳซ࿸֖ຏĂഴ͌ᛷࢴć

ܳซயሤүϡĂᆧΐਕณঐਈ ঽଈ

኎ି

ᐌᐠڇϡĂтϡᐠ̚ࢴۏ൑਌۹݋Ξ

ྯ࿅̙ڇĂ౵р੨ЪҲ਌۹฼ࢴ

ؠഇᑭߤҕᑅĂਔຨ ઘү

ϡ

਌۹ܮăႍڵă̂ܮѨᇴᆧΐăహܮă

ͪܮăཛ൭ăާܮຏ̈́ཛණ

੼ҕᑅă͕ଙăᐝ൭ă˾઀ăနࢴăܮ৪ăε

্

༰ԟ ӛќ̙։া࣏ཏĂᓙϗ៭႖ঽˠĂѣ ඪϮঽঽΫঽˠυืֹ͕̈ϡ

ଠטָ̙۞੼ҕᑅĂ৿ҕّ͕᝙ঽĂ͕᝙਽აĂ քඪΑਕᚑࢦள૱Ă͕ޠ̙ፋĂ̚ࢲ۞ঽΫ̈́

׌ฉ̰അڇϡ MAOI ٕ׎΁̚ᇽৠགྷࢴᇒԺט

጗ඈଐڶĂ৫֎ݭܦЍீ̈́ឩ⿔ঽ݋ࢋֹ͕̈

ϡ Ϲ̢

үϡ

਌໘ّჯϠ৵Ăɘࡧឍቾ৵Ă cyclosporin Ξਕົצᇆᜩ

MAOI, SSRIĂ̈́ົֹҕᑅ͕ྯᆧΐ̝ᘽ,ົԺ ט CYP3A4 ̝ᘽ(т ketoconazoleĂ

erythromycin) ᘃθ

ඈ৺

C ৺

ણ҂ྤफ़Ĉ!

1. Snow V,.Barry P, Fitterman N, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142:525

2. The Practical Guide. Identification, Evaluation, and Treatment of Overweight and obesity in Adults. NIH Publication Number 02-4084 Washington DC 2000.

3. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity.

Ann Intern Med 2005; 142:532.

4. ᐮ ܷ ᄒ ă ૺ ፮ ၷ Ĉ ഴ ۲ ̝ Ъ ந ϡ ᘽ ̈́ ϡ ᘽ щ Б ଣ ੅ Ă ᘽ ጯ ᗔ ᄫ Ă 2002 Sep,18(3):47~526.

5. Fernandez JR, Allison DB, 2004. Rimonabant Sanofi-Synthelabo. Curr Opin Invest Drugs 5:430-435.

3

中華民國九十六年一月 第十四卷 第一期 3

ROSUVASTATIN!

ѯؐऌ ᘽर

Rosuvastatin ߏ

3-hydroxy-3-methylglutaryl-Coenzyme A ĞHMG-CoAğ۞ᔘࣧ酶ᏴፄّᚮۋԺט

጗Ă͹ࢋүϡдք᝙Ăιਕᆧΐք௟ࡪܑ

ࢬ LDL ତצጡᇴϫĂܳซ LDL ۞ӛќ̶̈́

ྋ΃ᔁĂ֭Ժט VLDL дք᝙̝ЪјĂซ

҃ഴ͌ LDL ᄃ VLDL ௕̝̄ᓁᇴĂ͹ࢋዋ ᑕাࠎڼᒚ੼ᓙ׽ዔҕাă੼ˬᅕϟڵ਌

ҕাĄ

Rosuvastatin ڇ ϡ ͞ ё ࠎ ˾ ڇ 10mgĂՏ͇˘ѨĂѝ˯ٕ୎˯ڇϡĂΗ਽

ഇࠎ 19 ̈ॡĂڇϡ rosuvastatin ޢĂࡗ 3-5

̈ॡΞ྿౵੼፧ޘĂࢴۏ̙ᇆᜩ׎ӛќĄ ඪ᝙׶҉ّ߲҇ᄃ጗ณӔϒͧᙯܼĂᚑࢦ ඪΑਕ̙Б۞ଈ۰(CLcr<30mi/min)Ăᘽۏ ҕ̚፧ޘົᆧΐˬࢺĂޙᛉ੓ؕ጗ณࠎ 5mgĂໂณ̙෹࿅ l0mgĄΩγĂ၆ٺ̙ᅮ

ࢋ᎕ໂࢫҲᓙ׽ዔ۞ঽˠ̈́׍ѣயϠ҉ঽ តПᐍЯ̄۰ăТॡֹϡ cyclosporineăֲ

߷ˠٕߏඪΑਕ̙Б۰Ă੓ؕ጗ณᑕଂՏ

͟ 5 mg ฟؕĂͽࢫҲ҉҇ঽត̈́ፖ৳҉໘ ྋা۞൴Ϡ፟தĄ

Rosuvastatin д̙Т۞ˠ჌۞ᘽۏજ

˧ጯܑன̙ТĂϫ݈ࣧЯ̙ځĄ׶Ϩ჌ˠ

࠹ͧĂrosuvastatin дֲ߷ˠ۞ҕ̚፧ޘࠎ Ϩ჌ˠ۞ 2 ࢺĂٙͽֲ߷ˠдֹϡѩᘽݡ ॡĂ੓ؕ጗ณࠎ 5mgĂͷдአፋ጗ณॡĂ

ᅮࢋՀΐ͕̈Ą

Rosuvastatin གྷϤ CYP2C9 ΃ᔁćᘽ ۏ Ϲ ̢ ү ϡ Β ߁ Ă rosuvastatin ׀ ϡ cyclosporine ॡĂҕ̚፧ޘົ੼΍ 10 ࢺĂ ڇϡ rosuvastatin ͽ̙෹࿅ 5mg ࠎࣧ݋ć

׀ϡ gemfibrozil ޢĂົᆧΐ rosuvastatin ҕ ̚ ፧ ޘ Ă rosuvastatin ጗ ณ ͽ ̙ ෹ ࿅ 10mg ࠎࣧ݋ćᄃ׎΁ fibrate ᙷ׀ϡົᆧ ΐ҉҇ۆٕፖ৳҉໘ྋা۞ПᐍّĄ༊ᄃ warfarin ׀ϡॡĂϤٺ׌۰ౌߏགྷ CYP2C9

΃ᔁĂ̢࠹ᚮۋ˭Ăֹ଀ INRĞInternational Normalized Ratio ğ ົ ᆧ ΐ ˟ ࢺ Ą ༊ ᄃ antacids ׀ڇॡĂౄј rosuvastatin ҕ̚፧

ޘࢫҲ 50%Ă׌ᘽҌ͌࿣ฟ˟̈ॡڇϡĄ Rosuvastatin ૱֍۞ઘүϡĂΒ߁ݟ ಘۆĞ9%ğăᐝ൭Ğ6%ğăᐝຶă҉҇൭ Ğ3%ğăܮ৪ă⪰͕ăཛ൭ăঐ̼̙։ඈĄ ᘃθщБ̶৺ࠎ XĄΩγĂ65 ໐ͽ˯ăϥ ېཛྷ፟ਕҲ˭̈́ඪΑਕ̙։ঽˠĂдֹϡ statin ᙷᘽۏޢྵ׎΁ˠѣՀ੼፟த൴Ϡ

҉҇ঽតĂֹϡ rosuvastatin ॡĂᅮ͕̈Ⴞ

ീ׎ઘүϡĄтڍĂଈѣЯ߿જّքۆٕ

̙ځࣧЯ۞ҕ୻ঊૄᖼொᅔ৵޺ᜈ˯̿෹

࿅ϒ૱˯ࢨࣃ 3 ࢺͽ˯̈́҉҇ঽតଈ۰༰ ϡĄStatin ᙷࢫҕ਌ᘽۏĂώੰଳϡ۞׎΁

ј ̶ ѣ Ă atorvastatin ă simvastatin ̈́ pravastatinĂكѩม۞ͧྵྎтܢܑĄ ϡ ᘽ щ Б !

4

中華民國九十五年六月 第十三卷 第三期 5

ܑ˘Ĉέ̚ၷϔᓁᗁੰଳϡ statins ᙷࢫҕ਌ᘽۏ̝ͧྵ!

ј̶Щ Rosuvastatin 10mg

Atorvastatin 10mg

Simvastatin 40mg

Pravastatin 10mg

થݡЩ Crestor Lipitor Zocor Mevalotin јˠޙᛉ੓ؕ጗ณ 10mg QD 10mg QD 20mg QD 10-20mg QD

јˠޙᛉՏֹ͟ϡ

጗ณቑಛ 5-40mg 10-80mg 5-80mg 10-40mg јˠޙᛉՏ͟౵̂

጗ณ 40mg 80mg 80mg 80mg

׊ආޙᛉ጗ณ 18 ໐ͽ˭̙ޙ ᛉֹϡ

10-17 ໐̝੓ؕ

጗ณ 10mgĂ4 ฉ ̰ ు ႙ አ ፋ

጗ณĂ౵̂጗ณ 20mg

10-17 ໐̝੓ؕ

጗ณ 10mgĂჯ

޺ ጗ ณ

10-40mgĂ౵̂

጗ณ 40mg

8-13 ໐Տ͟጗

ณ 20mgĂ14-18 ໐ Տ ͟ ጗ ณ 40mg

ڇϡ͞ё

ѝٕ୎ڇϡ ࢴ ۏ ̙ ᇆ ᜩ ӛ ќ

༊ ᄃ antacids

׀ڇॡĂ׌ᘽҌ

͌ ࿣ ฟ ˟ ̈ ॡ ڇϡĄ

ѝٕ୎ڇϡ ࢴ ۏ ̙ ᇆ ᜩ ӛ ќ

Ⴢ݈ڇϡ ࢴ ۏ ̙ ᇆ ᜩ ӛ ќ

Ⴢ݈ڇϡ ࢴ ۏ ົ ࢫ Ҳ ӛ ќ

߿ّ΃ᔁۏ Yes Yes Yes No

ϠវΞϡதĞ%ğ 20 15 <5 17

కϨඕЪதĞ%ğ 88 >90 95 43-55

Η਽ഇĞ̈ॡğ 19 14 3 2.6-3.2

Ꮠ਌ّ Ꮠͪ Ꮠ਌ Ꮠ਌ Ꮠͪ

΃ᔁ͞ё CYP2C9 CYP3A4 CYP3A4 Sulfation ଵੵ͞ё

Ԍ ᒵܮ

10%

90%

2%

98%

13%

60%

20%

71%

ඪΑਕ̙։ॡٙᅮ

጗ณአፋ

Ccr<30ml/min

≤10mg/day ̙ᅮአፋ 5mg ฟؕ 10mg ฟؕ

ણ҂͛ᚥĈ

1. DrugDex under the title of Rosuvastatin, Micromedex Inc. March, 2006.

2. UpToDate under the title of Rosuvastatin, 2006.

3. The circular from the manufacturer of rosuvastatin.

第十四卷 第一期 台中榮總藥訊 6

ഴ۲ᘽ൴Ϡ̙։ͅᑕ۞έ៉གྷរ!

഼هസ ᘽर Orlistat ٺ 89 ѐ 11 ٺ͡έ៉˯ξĂ

sibutramine 91 ѐ 1 ͡ٺέ៉˯ξĄБ઼̙

։ͅᑕ఼ಡ͕̚ٺ 90 ѐҌ 94 ѐ 10 ͡Вќ ะ 50 Іᙯٺ orlistatĞ2 Іğ̈́ sibutramine Ğ48 Іğ۞̙։ͅᑕּ̄ć׎̚Ẵّҫ 48 ּĂշّ 2 ּĂࡗ 80%۞̙։ͅᑕ൴Ϡ ٺ 20-49 ໐۞ଈ۰Ą

̶ژ orlistat ̈́ sibutramine 4 ѐέ៉൴ Ϡ̙։ͅᑕᚑࢦޘ۞གྷរĂᅅޘҫ 40%Ă̚

ޘҫ 30%̈́ࢦޘҫ 6%ć͹ࢋ۞఍ཉ͞ёߏ

ͽઃᘽࠎ͹Ğ54%ğĂ12%ᅮࢋග̟ᘽۏڼ ᒚĄsibutramine ྵᚑࢦ۞ႷҬᓜԖাېѣ ײӛӧᙱă҉҇ᆉۡă൯᝾ăෛ˧ሀቘ̈́Ϩ

̰ᅪăܮ৪̈́⢜გă߹யĄOrlistat ۞ 2 ࣎

̙։ͅᑕ̶Ҿࠎ̂ܮε༰̈́քΑਕள૱ĞႷ Ҭ orlistat ͔੓ ASTăALT ˯̿Ă̶Ҿࠎ 186U/Lă460U/LĂٺઃᘽޢĂ3 ฉޭೇĂ൒

҃Я׎ڇᘽ݈՟ѣ࠹ᙯᑭរΞֻણ҂ĂЯѩ

࠹ᙯّᙱͽෞҤĄğĄᖼᐂҋᘽۏщБᖎੈ

2005ć12Ĉ20-27.

95 ѐ 10-12 ͡າ˯ቢᘽݡ

ี

Ѩ ˯ቢາᘽᘽЩ ᄦౄᇄ ᘽቅ ઉܲᆊ ᄲځ

1 Oxalip inj 50mg

(Oxaliplatin) έ៉ڌ߶ AO100 6891.00

ዋᑕাĈͽ FLUOROPYRIMIDINES ᙷᘽۏڼᒚεୀ̝ᖼொّඕབۡབ ᒛĂ׶ 5-FLUOROURACIL ׶ FOLINIC ACID ׀ϡĂௐ˘ቢڼᒚᖼ

ொّඕབۡབᒛĄᄃ

5-FLUOROURACIL ׶ FOLINIC ACID ׀ϡĂүࠎௐˬഇඕབᒛଈ۰͘

ఙޢ۞ᅃӄّᒚڱĄ

2

Cromolyn eye drops 10ml (Allergo-COMO D)

URSAPHA

RM AI370 ൑ ዋᑕাĈ࿅ୂّඕቯۆĄ ᘽ ݡ ள જ !

ϡ ᘽ щ Б !

第四卷 第一期 台中榮總藥訊 7

3

Systane eye drops 15ml (Polyethylene Glycol 400 &

Proylene Glycol)

ALCON AS970 ൑ ዋᑕাĈᇶॡቤྋЯீ༗઀ᒁ͔ٙ੓

۞լሤຏᄃו፬ຏĄ

4

KI-Flu inj 0.5ml (Influenza inactive vaccine)

઼ЍϠԫ AK340 ൑ ዋᑕাĈ࿰֨߹Җّຏ݂

5

LantusOptiset 300U (Insulin glargine)

SANOFI-A

VENTIS AI230 454.00 ዋᑕাĈᎤԌঽĄ

6

Kalimate powder 5g (Calcium polystyrene sulfonate)

NIKKEN AK330 14.00 ዋᑕাĈާّ̈́ၙّඪ̙Бᐌҡ̝੼

ҕ࿔াĄ

7

Zometa inj 4mg/5ml (Zoledronic acid)

NOVARTIS AZ110 12384.00

ዋᑕাĈ1.ڼᒚೋّཚሳ̝੼ҕถ׀

൴া(HCM)Ą 2.੫၆ MULTIPLE MYELOMA, BREAST CANCER, PROSTATE CANCER ൴Ϡٺ੻ᐪٕ

யϠ੻ᖼொ̝ঽଈĂΞ࿰֨׎੻ᐪצ

ְ๋ІĄ

8

Nifecardia tab-30 (Nifedipine)

઼̼̚ጯ AN330 14.50 ዋᑕাĈব͕াă੼ҕᑅĄ

9

Safepril tab 10mg (Lisinopril)

Ϡ྿ AL650 11.70 ዋᑕাĈ੼ҕᑅă·ҕّ͕᝙਽აă

ާّ͕҉ୟ๫Ą

10 Zocor tab 40mg

(Simvastatin) MSD AS680 46.70

ዋᑕাĈ੼ᓙ׽ዔҕাă੼ˬᅕϟڵ

⟯ҕাĄ

第十四卷 第一期 台中榮總藥訊 8

Бϔઉ૵ܲᐍᘽݡග;ఢؠ࣒ϒఢؠ!

ௐ˘ౢ ৠགྷր௚ᘽۏ Drugs acting on the nervous system

)ҋ˝Ȉ̱ѐ˘͡˘͟੓߉Җ*!

൴͛͟ഇĈ̚රϔ઼ 95 ѐ 12 ͡ 1 ͟

൴͛фཱིĈઉܲᘽфௐ 0950030859 ཱི

າ࣒ϒග;ఢؠ ࣧග;ఢؠ

1.1.5.ܧᙷ׽ዔԩ൴ۆ጗ĞNSAIDsğᘽݡ Ğ т celecoxib ă nabumetone ă meloxicamăetodolacănimesulideğ (90/7/1) etoricoxib(96/01/1)

1.ώᙷᄦ጗ֹ̝ϡᅮЪͼ኎Ϡ͹გ፟ᙯ ధΞ̝ዋᑕাቑಛĂ֭௑Ъ˭Е୧І

̝˘۰Ĉ

(1) ѐ᛬̂ٺඈٺ̱Ȉ໐̝੻ᙯ༼ۆঽ ଈĄ

(2)ᙷࢲᒅّᙯ༼ۆăᆉّۡਖលۆă઀

ᝓّᙯ༼ۆඈၙّঽ൴ۆّᙯ༼ঽ តĂᅮܜഇֹϡܧᙷ׽ዔԩ൴ۆ጗۰Ą (3)Ъ׀ѣާّᚑࢦ౹๋ă̚ࢲ͕̈́ҕგ

়ঽ۰Ą

(4)Тॡ׀ѣඪ˯ཛྷᙷ׽ዔ̝ଈ۰Ą (5)അѣঐّ̼ሚႹă˯ঐ̼྽΍ҕٕࡤ

ࡍ͋ঽΫ۰Ą

(6)Тॡ׀ѣԩᑢҕ጗۰Ą (7)քർ̼ଈ۰Ą

2.ֹϡώᙷᄦ጗̝ঽଈ̙଀࿰ّ֨׀ϡ˙

ݭ௡ᖐ῔צវܡᕝ጗ă୰ᗓ̄ᑒ঒ܡᕝ጗

̈́׎΁ঐّ̼ሚႹϡᘽĂϺ̙଀Ъ׀ֹϡ

݈Еཛྷ৵጗Ğт misoprostolğ

1.1.5.ܧᙷ׽ዔԩ൴ۆ጗ĞNSAIDsğᘽݡĞт celecoxibănabumetoneămeloxicamă etodolacănimesulideğĈ(90/7/1)

1.ώᙷᄦ጗ֹ̝ϡᅮЪͼ኎Ϡ͹გ፟ᙯధΞ̝

ዋᑕাቑಛĂ֭௑Ъ˭Е୧І̝˘۰Ĉ (1)ѐ᛬̂ٺඈٺ̱Ȉ໐̝੻ᙯ༼ۆঽଈĄ (2)ᙷࢲᒅّᙯ༼ۆăᆉّۡਖលۆă઀ᝓّᙯ

༼ۆඈၙّঽ൴ۆّᙯ༼ঽតĂᅮܜഇֹϡ ܧᙷ׽ዔԩ൴ۆ጗۰Ą

(3)Ъ׀ѣާّᚑࢦ౹๋ă̚ࢲ͕̈́ҕგ়ঽ۰Ą (4)Тॡ׀ѣඪ˯ཛྷᙷ׽ዔ̝ଈ۰Ą

(5)അѣঐّ̼ሚႹă˯ঐ̼྽΍ҕٕࡤࡍ͋ঽ Ϋ۰Ą

(6)Тॡ׀ѣԩᑢҕ጗۰Ą (7)քർ̼ଈ۰Ą

2.ֹϡώᙷᄦ጗̝ঽଈ̙଀࿰ّ֨׀ϡ˙ݭ௡ᖐ

῔צវܡᕝ጗ă୰ᗓ̄ᑒ঒ܡᕝ጗̈́׎΁ঐّ̼

ሚႹϡᘽĂϺ̙଀Ъ׀ֹϡ݈Еཛྷ৵጗Ğт misoprostol

౯ොĈထቢొ̶ࠎາ࣒ࢎٕפঐ̝ఢؠ ঐ ि ಡ ጱ !